Herbst RS, et al. - In patients with previously treated advanced gastric or gastro-esophageal junction adenocarcinoma, non-small-cell lung cancer, or urothelial carcinoma, researchers tested ramucirumab (an IgG1 VEGF receptor-2 antagonist) in combination with pembrolizumab (an IgG4 PD-1 antagonist) for safety and preliminary antitumor activity. This multicohort, non-randomized, open-label, phase 1a/b trial was run at 16 academic medical centers, hospitals, and clinics in the US, France, Germany, Spain, and the UK. In patients with previously treated advanced gastric or gastro-esophageal junction adenocarcinoma, non-small-cell lung cancer, and urothelial carcinoma, findings revealed a favorable antitumor activity as well as a manageable safety profile of ramucirumab combined with pembrolizumab. Dual inhibition of the VEGF–VEGFR2 and PD-1–PD-L1 pathways is supported by the findings.